Should You Consider Holding Myriad Genetics (MYGN) Stock in Your Portfolio?
Myriad Genetics, Inc. (MYGN) is focused on expanding its presence in companion diagnostics, growing its Oncology business through new clinical guidelines, and launching innovative new products. The company aims to sustain long-term growth through strategic investments in scientific research, tech-driven operations, and scalable infrastructure. Its strong solvency profile further strengthens the stock’s outlook. However, the loss of UnitedHealthcare’s coverage for GeneSight and ongoing macroeconomic pressures pose notable risks.
Over the past year, shares of this Zacks Rank #3 (Hold) company have plunged 79%, significantly underperforming the broader industry, which fell 12.6%, and the S&P 500, which rose 9.2%.
Despite the stock’s struggles, Myriad Genetics continues to lead in genetic testing and precision medicine with a market capitalization of $463.7 million. The company boasts a modest earnings yield of 0.2%, still outperforming the industry average of -29.4%, and has delivered earnings surprises in each of the past four quarters—averaging an impressive 210% beat.
Tailwinds Supporting MYGN
Strong Growth in Oncology Testing
Myriad sees significant growth opportunities in serving community oncologists and healthcare systems, particularly through its hereditary cancer and homologous recombination deficiency (HRD) tests. A key development came in February 2025, when Myriad partnered with Gabbi to integrate Gabbi’s risk assessment tools with MyRisk and RiskScore offerings. Additionally, with the integration of PATHOMIQ’s AI platform, Myriad becomes the only provider to offer AI biomarkers, germline, and tumor profile testing under one roof.
The updated NCCN (National Comprehensive Cancer Network) guidelines now include the Prolaris test for low to high-risk prostate cancer patients at the time of biopsy—a notable validation.
Further strengthening its oncology pipeline, Myriad secured two new patents for its Minimal Residual Disease (MRD) solution, adding to three awarded last year. The Precise MRD test is on track for a first-half 2026 launch, alongside Precise Liquid, a liquid biopsy therapy selection test.
Strategic Advancements and Partnerships
In Q1 2025, MyRisk testing volumes rose 11% year over year. The company’s internally developed products—Prequel, FirstGene, and the upcoming Precise MRD—are expected to be major growth drivers. A recent partnership with PATHOMIQ, Inc., focused on AI-driven prognostic and predictive tools, complements these initiatives.
Myriad’s women’s health segment also holds strong potential. The MyRisk hereditary cancer screening alone could serve 50 million U.S. women eligible under current guidelines. Prenatal testing revenue grew 11% year over year in Q1, bolstered by partnerships with JScreen and Cancer Care.
The company is also investing in electronic medical record (EMR) integration to improve both provider and patient experience, which is expected to drive future test volumes.
Healthy Financial Position
As of Q1 2025, Myriad held $92 million in cash and cash equivalents and carried no short-term debt. This strong liquidity provides a buffer against economic headwinds and ensures capacity for strategic investment.
What’s Weighing on MYGN?
Macroeconomic Headwinds
Myriad’s global operations expose it to a range of regulatory, political, and economic challenges. Inflation continues to pressure labor costs, lab supplies, and testing-related expenses. Additionally, rising U.S. tariffs could dent profitability if the company is unable to pass those costs onto customers.
Loss of GeneSight Coverage
Effective November 1, 2024, UnitedHealthcare ceased coverage for multi-gene panel pharmacogenetic tests—including GeneSight—across several plans. This change led to a 20% year-over-year decline in GeneSight revenue in Q1 2025 and presents a significant threat to this revenue stream moving forward.
Analyst Estimates and Outlook
Over the past 30 days, the Zacks Consensus Estimate for Myriad’s 2025 earnings has been revised downward by 3 cents, now standing at just $0.01. Revenue projections for 2025 are pegged at $811.7 million, suggesting a 3.1% decline compared to the previous year.
Better-Ranked MedTech Alternatives
For investors seeking stronger options within the medical technology space, the following stocks hold higher Zacks rankings:
Phibro Animal Health (PAHC) – Zacks Rank #1 (Strong Buy)
Long-term earnings growth forecast: 26%
Average surprise over past 4 quarters: 30.6%
Stock performance: +38.9% vs. +10.1% industry gain
Hims & Hers Health (HIMS) – Zacks Rank #2 (Buy)
Earnings yield: 1.3% vs. industry -10.1%
Stock performance: +129.7% vs. +35.9% industry gain
Cencora (COR) – Zacks Rank #2 (Buy)
Earnings yield: 5.4% vs. 3.8% for the industry
Stock performance: +25.9%, outperforming the industry’s -14.4%
